Trials / Completed
CompletedNCT02417831
Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.
Single Center, Single Dose, Open-label, Randomized, Two-way Crossover Study to Determine Bioequivalence of Two Formulations Containing Tamsulosin HCl 04.mg MR Capsules in at Least 30 Healthy Male Subjects Under Fasted Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
A bio-equivalence of 2 different capsule formulations in fasted subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tamsulosin capsules | |
| DRUG | tamsulosin HCl |
Timeline
- Start date
- 2015-04-30
- Primary completion
- 2015-05-31
- Completion
- 2015-05-31
- First posted
- 2015-04-16
- Last updated
- 2020-04-27
- Results posted
- 2020-03-26
Source: ClinicalTrials.gov record NCT02417831. Inclusion in this directory is not an endorsement.